INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 433m ago
HOUSE PTR33m ago
SEC 13F32m ago
ROBINHOOD CHAIN32m ago
Public company

KRYSKrystal Biotech, Inc.

CIK 0001711279

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 2
Max Insider Score20
Connections5with evidence

KRYS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
MC
Mason ChristopherDirector
KRYSKrystal Biotech, Inc.
Grant or award
A—
471 sh
Sep 14, 2026Sep 16, 2026
traded Sep 14, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Mazzacco CatherineDirector · Sep 16, 2026
  • ← Insider ofevidence
    Sutherland Everett RandDirector · Sep 16, 2026
  • ← Insider ofevidence
    Mason ChristopherDirector · Sep 16, 2026
9
SR
Sutherland Everett RandDirector
KRYSKrystal Biotech, Inc.
Grant or award
A
—
471 sh
Sep 14, 2026
Sep 16, 2026
traded Sep 14, 2026
+2d
SEC FORM 4

Evidence

9
MC
Mazzacco CatherineDirector
KRYSKrystal Biotech, Inc.
Grant or award
A—
1,187 sh
Sep 14, 2026Sep 16, 2026
traded Sep 14, 2026
+2dSEC FORM 4

Evidence

9
MC
Mazzacco CatherineDirector
KRYSKrystal Biotech, Inc.
Grant or award
A—
471 sh
Sep 14, 2026Sep 16, 2026
traded Sep 14, 2026
+2dSEC FORM 4

Evidence

9
SR
Sutherland Everett RandDirector
KRYSKrystal Biotech, Inc.
Grant or award
A—
1,187 sh
Sep 14, 2026Sep 16, 2026
traded Sep 14, 2026
+2dSEC FORM 4

Evidence

9
MC
Mason ChristopherDirector
KRYSKrystal Biotech, Inc.
Grant or award
A—
1,187 sh
Sep 14, 2026Sep 16, 2026
traded Sep 14, 2026
+2dSEC FORM 4

Evidence

0
TC
Thomas John CharlesEVP, General Counsel
KRYSKrystal Biotech, Inc.
Option exercise · 10b5-1 plan
M—
1,000 sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

0
TC
Thomas John CharlesEVP, General Counsel
KRYSKrystal Biotech, Inc.
Option exercise · 10b5-1 plan
M$179K
1,000 sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

19
TC
Thomas John CharlesEVP, General Counsel
KRYSKrystal Biotech, Inc.
Open-market sale · 10b5-1 plan
SELL$347K
1,000 sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

20
TC
Thomas John CharlesEVP, General Counsel
KRYSKrystal Biotech, Inc.
Open-market sale · 10b5-1 plan
SELL$194K
642 sh
May 26, 2026May 27, 2026
traded May 26, 2026
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Thomas John CharlesEVP, General Counsel · May 27, 2026